Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical Inc is positioned for potential growth driven by faster-than-expected developments in the spine market and strong sales from its Enabling Technologies, with projections indicating a sequential improvement in sales. The company's robust performance in the U.S. spine sector and an impressive 10% growth in Nevro sales highlight its strong market presence and product demand. With anticipated improvements in organic growth, strong free cash flow, and the strategic benefits of ongoing integration efforts, the company is likely to achieve improved EBITDA margins and revenue growth, enhancing its overall financial outlook.

Bears say

Globus Medical faces several fundamental risks that contribute to a negative outlook on its stock, including slower-than-expected growth in the spine market and potential revenue disruptions due to the mergers of NuVasive and Nevro. The bear case scenario indicates a concerning trend of revenue growth slowing to low-single digits while margins are expected to remain flat, highlighting the potential for financial underperformance. Furthermore, significant challenges such as competitive dynamics, ineffective product launches, and delays in expanding into new musculoskeletal areas could adversely affect the company’s operational and financial metrics.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.